Literature DB >> 1093653

In vitro sensitivity of hemophilus influenzae and streptococcus pyogenes to co-trimoxazole.

W D Leers.   

Abstract

The invitro testing of Hemophilus influenzae and Streptococcus pyogenes for co-trimoxazole sensitivity requires certain "defined" media that have to be free of inhibitory substances. The use of Columbia agar base with Fildes extract for H. influenzae or of blood agar for S. pyogenes may produce "false-resistant" strains. The addition of thymidine phosphorylases in the form of gentlylysed horse blood (2 to 10%) does not remove all inhibitors in those tests, especially where "undefined" agar bases are used, and results in scanty growth of H. influenzae; the addition of more than 2% results in dark plates, making reading of sensitivities difficult. Fildes agar for testing H. influenzae may be made with enriched sheep or horse blood if the proper "defined" agar base is used. The use of Wellcotest or DST (Oxoid) agar is recommended with Fildes extract for H. influenzae or with blood for S. pyogenes for in vitro testing for co-trimoxazole sensitivity. The addition of thymidine phosphorylase in the form of 2% lysed horse blood does not interfere with reading. However, it results in scanty growth of H. influenzae. Proper inoculation of plates is important. The growth on the plates should be light, dense, but not confluent. Heavy growth may render some strains "false-resistant" even when defined media are used. Our results indicate that many of the previously reported resistant strains of H. influenzae and S. pyogenes may have been "false-resistant" because of the use of "undefined" media. We believe that, in view of our results, respiratory infections may be treated with co-trimoxazole until bacteriologic studies prove that this treatment is contraindicated, since H. influenzae and S. pyogenes are usually found sensitive in vitro under proper conditions.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1093653      PMCID: PMC1956454     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  9 in total

1.  Haemophilus influenzae apparently resistant to trimethoprim.

Authors:  S R Bushby
Journal:  Br Med J       Date:  1973-07-07

2.  Resistance of Haemophilus influenzae to trimethoprim.

Authors:  J R May; J Davies
Journal:  Br Med J       Date:  1972-08-12

3.  Practical aspects of testing sensitivity to trimethoprim and sulphonamide.

Authors:  P M Waterworth
Journal:  Postgrad Med J       Date:  1969-11       Impact factor: 2.401

4.  Trimethoprim, a sulphonamide potentiator.

Authors:  S R Bushby; G H Hitchings
Journal:  Br J Pharmacol Chemother       Date:  1968-05

5.  Combined antibacterial action in vitro of trimethoprim and sulphonamides. The in vitro nature of synergy.

Authors:  S R Bushby
Journal:  Postgrad Med J       Date:  1969-11       Impact factor: 2.401

6.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

7.  Reversal of the antimicrobial activity of trimethoprim by thymidine in commercially prepared media.

Authors:  A E Koch; J J Burchall
Journal:  Appl Microbiol       Date:  1971-11

8.  Trimethoprim: laboratory and clinical studies.

Authors:  J H Darrell; L P Garrod; P M Waterworth
Journal:  J Clin Pathol       Date:  1968-03       Impact factor: 3.411

9.  Effect of medium composition on the apparent sensitivity of Pseudomonas aeruginosa to gentamicin.

Authors:  L P Garrod; P M Waterworth
Journal:  J Clin Pathol       Date:  1969-09       Impact factor: 3.411

  9 in total
  2 in total

Review 1.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

2.  Revisiting the inoculum effect for Streptococcus pyogenes with a hollow fibre infection model.

Authors:  Darcy Marum; Laurens Manning; Edward Raby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-05-04       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.